1999 to 2020 Saw Decrease in Mortality Due to Infective Endocarditis
By Elana Gotkine HealthDay Reporter
THURSDAY, Dec. 14, 2023 -- From 1999 to 2020, there was a decrease in the rate of mortality due to infective endocarditis (IE) overall, but a significant acceleration was seen for those aged 25 to 44 years, according to a study published online Dec. 13 in the Journal of the American Heart Association.
Muchi Ditah Chobufo, M.D., M.P.H., from West Virginia University Heart & Vascular Institute in Morgantown, and colleagues reviewed multiple causes of death data from the U.S. Centers for Disease Control and Prevention's Wide-Ranging Online Data for Epidemiologic Research database from 1999 to 2020.
The researchers observed a decline in the IE-related age-adjusted mortality rates between 1999 and 2020. In the age groups 25 to 34 and 35 to 44 years, IE-related crude mortality accelerated significantly (average annual percentage changes, 5.4 and 2.3, respectively), but no change was seen for those aged 45 to 54 years (average annual percentage change, 0.5); a significant decline was seen for those aged ≥55 years. In the 25- to 44-year age group, those with IE had an increase in concomitant substance use disorder as multiple causes of death. In contrast with other states, which had a decline or static trend for IE, the states of Kentucky, Tennessee, and West Virginia showed an acceleration in age-adjusted mortality rates.
"The impact of multipronged harm-reduction programs on IE-related mortality trends in the most productive age groups and in certain states remains to be seen," the authors write.
One author disclosed ties to Abbott.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.